Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
SAGE Therapeutics (SAGE) Stock Price & Analysis
857 Followers
SAGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.92 - $59.99
Previous Close$11.7
Volume936.66K
Average Volume (3M)1.01M
Market Cap
$704.13M
Enterprise Value-$164.96M
Total Cash (Recent Filing)$876.05M
Total Debt (Recent Filing)$6.97M
Price to Earnings (P/E)-1.4
Beta0.98
Next Earnings
Aug 06, 2024EPS Estimate
-$1.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.40
Shares Outstanding60,182,031
10 Day Avg. Volume937,577
30 Day Avg. Volume1,012,446
Standard Deviation0.16
R-Squared0.09
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.89
Price to Sales (P/S)245.85
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-14.55
Enterprise Value/Gross Profit-21.46
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$19.29Price Target Upside64.87% Upside
Rating ConsensusHold
Number of Analyst Covering17
SAGE Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceZurzuvae sales exceed expectations with robust market reception, as demonstrated by the significant sales figures reported.
Market CoverageZurzuvae has achieved rapid commercial coverage expansion, with a majority of commercial lives now insured under payor policies.
Product AdoptionZurzuvae is solidifying its position as a first-line treatment in postpartum depression, gaining traction among OBGYNs and patients.
Bears Say
Clinical TrialsUpcoming clinical trial results carry more risk, highlighting the need for meaningful clinical validation.
Company GuidanceThe company has taken a more conservative stance on dalzanemdor following failure in the PRECEDENT study, reducing the price target.
Stock PerformanceAnalyst reiterates Underperform rating, signaling skepticism about the stock's future performance.
---
Ownership Overview
7.91% Insiders
35.35% Mutual Funds
49.22% Other Institutional Investors
7.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $10.92 and its highest was $59.99 in the past 12 months.
What is SAGE Therapeutics’s market cap?
Currently, no data Available
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 80 days.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on Apr 25, 2024. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$1.649 by -$0.151.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate is -$1.66.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 60,182,030 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$1.8 in its last earnings report, missing expectations of -$1.649. Following the earnings report the stock price went down -3%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Among the largest hedge funds holding SAGE Therapeutics’s share is Fisher Asset Management LLC. It holds SAGE Therapeutics’s shares valued at 8M.
---
SAGE Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.29 (64.87% Upside)
$19.29 (64.87% Upside)
Blogger Sentiment
Bullish
SAGE Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 641.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.64%
12-Months-Change
Fundamentals
Return on Equity
-54.72%
Trailing 12-Months
Asset Growth
-37.12%
Trailing 12-Months
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
SAGE Company Deck
---
SAGE Earnings Call
Q1 2024
0:00 / 0:00
---
SAGE Stock 12 Month Forecast
Average Price Target
$19.29
▲(64.87% Upside)
Technical Analysis
Best Analysts Covering SAGE
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
-10.13%
reiterated a sell rating 24 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -10.13% per trade.
---